美国院外癫痫持续状态咪达唑仑实际使用与结局
该回顾性队列研究利用ESO数据协作组2019年1月1日至12月31日数据,纳入7,634例次来自657个急救机构的成人癫痫持续状态院外救治。暴露为咪达唑仑给药途径和剂量,采用分层逻辑回归和以机构治疗模式为工具变量的两阶段最小二乘法分析。结果显示,与肌注相比,经鼻给药增加抢救治疗风险(RD 6.5%,95%CI 2.4%至10.5%),静脉给药降低抢救治疗风险(RD -11.1%,95%CI -14.7%至-7.5%);通气支持差异无统计学意义。较高剂量与较低抢救治疗风险(RD -2.6%,95%CI -3.3%至-1.9%)和增加通气支持(RD 0.4%,95%CI 0.1%至0.7%)相关;工具变量分析结果相似,但剂量与通气支持无关。
要点
- 与肌注相比,经鼻咪达唑仑增加院外癫痫持续状态抢救治疗风险(RD 6.5%,95%CI 2.4%至10.5%)。
- 与肌注相比,静脉咪达唑仑降低抢救治疗风险(RD -11.1%,95%CI -14.7%至-7.5%)。
- 较高剂量咪达唑仑与较低抢救治疗风险相关(RD -2.6%,95%CI -3.3%至-1.9%),但增加通气支持(RD 0.4%,95%CI 0.1%至0.7%)。
- 经鼻与静脉给药相比肌注,通气支持风险差异无统计学意义(经鼻RD -1.5%,95%CI -3.2%至0.3%;静脉RD -0.3%,95%CI -1.9%至1.2%)。
- 工具变量分析结果相似,但剂量与通气支持无关联。
适用人群与场景
- 成人癫痫持续状态院外救治,数据来自ESO数据协作组2019年1月1日至12月31日,共7,634例次,来自657个急救机构。
研究设计与关键结果
- 回顾性队列研究,纳入7,634例次院外成人癫痫持续状态,来自657个急救机构;咪达唑仑经鼻给药占20%,静脉给药占46%,肌注给药占35%。
- 与肌注相比,经鼻给药增加抢救治疗风险(RD 6.5%,95%CI 2.4%至10.5%),静脉给药降低抢救治疗风险(RD -11.1%,95%CI -14.7%至-7.5%)。
- 与肌注相比,经鼻和静脉给药在通气支持风险上差异无统计学意义(经鼻RD -1.5%,95%CI -3.2%至0.3%;静脉RD -0.3%,95%CI -1.9%至1.2%)。
- 较高剂量与较低抢救治疗风险相关(RD -2.6%,95%CI -3.3%至-1.9%),与增加通气支持相关(RD 0.4%,95%CI 0.1%至0.7%)。
- 工具变量分析结果相似,但剂量与通气支持无关联。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与肌注相比,经鼻给药可能效果较差,静脉给药可能更有效终止癫痫持续状态,但这些差异与既往结果的差异可能反映真实世界数据与随机数据的性质不同。
指南或共识出处
- 指南推荐10 mg肌注咪达唑仑作为癫痫持续状态的一线治疗选择(原文引用,未注明指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: Guidelines recommend 10-mg intramuscular midazolam as the first-line treatment option for status epilepticus. However, in real-world practice, it is frequently administered intranasally or intravenously and is dosed lower. Therefore, we used conventional and instrumental variable approaches to examine the effectiveness of midazolam in a national out-of-hospital cohort.
METHODS: This retrospective cohort study of adults with status epilepticus used the ESO Data Collaborative research dataset (January 1, 2019, to December 31, 2019). The exposures were the route and dose of midazolam. We performed hierarchical logistic regression and 2-stage least squares regression using agency treatment patterns as an instrument to examine our outcomes, rescue therapy, and ventilatory support.
RESULTS: There were 7,634 out-of-hospital encounters from 657 EMS agencies. Midazolam was administered intranasally in 20%, intravenously in 46%, and intramuscularly in 35% of the encounters. Compared with intramuscular administration, intranasal midazolam increased (risk difference [RD], 6.5%; 95% confidence interval [CI], 2.4% to 10.5%) and intravenous midazolam decreased (RD, -11.1%; 95% CI, -14.7% to -7.5%) the risk of rescue therapy. The differences in ventilatory support were not statistically significant (intranasal RD, -1.5%; 95% CI, -3.2% to 0.3%; intravenous RD, -0.3%; 95% CI, -1.9% to 1.2%). Higher doses were associated with a lower risk of rescue therapy (RD, -2.6%; 95% CI, -3.3% to -1.9%) and increased ventilatory support (RD, 0.4%; 95% CI, 0.1% to 0.7%). The instrumental variable analysis yielded similar results, except that dose was not associated with ventilatory support.
CONCLUSION: The route and dose of midazolam affect clinical outcomes. Compared with intramuscular administration, intranasal administration may be less effective and intravenous administration more effective in terminating status epilepticus, although the differences between these and previous results may reflect the nature of real-world data as opposed to randomized data.
参考来源
- Guterman EL, Sporer KA, Newman TB, et al. Real-World Midazolam Use and Outcomes With Out-of-Hospital Treatment of Status Epilepticus in the United States. Ann Emerg Med. 2022. PMID: 35931608. doi:10.1016/j.annemergmed.2022.05.024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。